Welcome To
Target Systemic Mastocytosis
Comprehensive Peer-Developed Educational Resources
About Systemic Mastocytosis
Mission Statement
The mission of Target Systemic Mastocytosis is to provide rigorous, comprehensive educational resources about systemic mastocytosis to healthcare professionals who may encounter these patients in their practice. Educational resources are developed by the Target SM committee, a group of physicians with expertise in systemic mastocytosis that represent a wide range of specialties. Blueprint Medicines provides financial support to the Target Systemic Mastocytosis Committee in the generation of this content.
What is Systemic Mastocytosis?
Clinical Perspectives
Systemic mastocytosis is a rare, clonal mast cell neoplasm driven by the KIT D816V mutation in 95% of patients. In patients with systemic mastocytosis, abnormal mast cell activation and uncontrolled mast cell proliferation result in unpredictable, debilitating symptoms.1-4
To learn more about systemic mastocytosis, please click the link below and explore the “Systemic Mastocytosis: Disease State Overview” slide module.
References: 1. Vaes M et al. Front Med. 2017;4:110. 2. Jara-Acevedo M et al. Mod Pathol. 2015;28(8):1138-1149. 3. Garcia-Montero AC et al. Blood. 2006;108(7):2366-2372. 4. Jennings SV et al. Immunol Allergy Clin North Am. 2018;38(3):505-525.
Allergist/
Immunologist
Cem Akin,
MD, PHD
Systemic Mastocytosis Diagnosis and Treatment:
An Allergist/
Immunologist's Perspective
Hematologist/
Oncologist
Daniel Deangelo,
MD, PHD
Systemic Mastocytosis Diagnosis and Treatment:
A Hematologist/
Oncologist's Perspective
Pathologist
Tracy George,
MD
Systemic Mastocytosis Diagnosis and Treatment:
A Pathologist's Perspective
What is Systemic Mastocytosis
Systemic mastocytosis is a rare, clonal mast cell neoplasm driven by the KIT D816V mutation in 95% of patients. In patients with systemic mastocytosis, abnormal mast cell activation and uncontrolled mast cell proliferation result in unpredictable, debilitating symptoms.1-4
To learn more about systemic mastocytosis, please click the link below and explore the “Systemic Mastocytosis: Disease State Overview” slide module.
References: 1. Vaes M et al. Front Med. 2017;4:110. 2. Jara-Acevedo M et al. Mod Pathol. 2015;28(8):1138-1149. 3. Garcia-Montero AC et al. Blood. 2006;108(7):2366-2372. 4. Jennings SV et al. Immunol Allergy Clin North Am. 2018;38(3):505-525.
Clinical Prespectives
Allergist/
Immunologist
Cem Akin,
MD, PHD
Systemic Mastocytosis Diagnosis and Treatment:
An Allergist/
Immunologist's Perspective
Hematologist/
Oncologist
Daniel Deangelo,
MD, PHD
Systemic Mastocytosis Diagnosis and Treatment:
A Hematologist/
Oncologist's Perspective
Pathologist
Tracy George,
MD
Systemic Mastocytosis Diagnosis and Treatment:
A Pathologist's Perspective
What is Systemic Mastocytosis?
Systemic mastocytosis is a rare, clonal mast cell neoplasm driven by the KIT D816V mutation in 95% of patients. In patients with systemic mastocytosis, abnormal mast cell activation and uncontrolled mast cell proliferation result in unpredictable, debilitating symptoms.1-4
To learn more about systemic mastocytosis, please click the link below and explore the “Systemic Mastocytosis: Disease State Overview” slide module.
References: 1. Vaes M et al. Front Med. 2017;4:110. 2. Jara-Acevedo M et al. Mod Pathol. 2015;28(8):1138-1149. 3. Garcia-Montero AC et al. Blood. 2006;108(7):2366-2372. 4. Jennings SV et al. Immunol Allergy Clin North Am. 2018;38(3):505-525.
Clinical Perspectives
Systemic MastoCytosis
Diagnosis and Treatment:
An Allergist/
Immunologist’s
Perspective
Cem Akin, MD, PHD
Systemic MastoCytosis
Diagnosis and Treatment:
A Hematologist/
Oncologist’s Perspective
Daniel Deangelo, MD, PHD
Systemic MastoCytosis
Diagnosis and Treatment:
A Pathologist’s
Perspective
Tracy George, MD
The Target Systemic
Mastocytosis Committee
A group of experts who lead development of the educational resources found on “TargetSM.com.” The committee is made up of physicians from multiple specialties who have extensive experience diagnosing and treating patients with systemic mastocytosis.
The Target Systemic
Mastocytosis Committee
A group of experts who lead development of the educational resources found on “TargetSM.com.” The committee is made up of physicians from multiple specialties who have extensive experience diagnosing and treating patients with systemic mastocytosis.
Sponsored by:
Blueprint Medicines, TargetSM.com and associated logos are trademarks of Blueprint Medicines Corporation.
© 2020 Blueprint Medicines Corporation.
07/2020 USBP-PRSM-20.001.1
Sponsored by:
Blueprint Medicines, TargetSM.com and associated logos are trademarks of Blueprint Medicines Corporation.
© 2020 Blueprint Medicines Corporation.
07/2020 USBP-PRSM-20.001.1
